GlassScriptPhysician profile
Kirk R Steptoe
NPI 1942212949
$4,831.36
in general payments reported to CMS, 2019-2025
38 companies · $902 in 2025
The $902 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $790 · 2020: $164 · 2022: $634 · 2023: $1,291 · 2024: $1,050 · 2025: $902.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,243.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $635.53 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $606.18 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $448.06 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $397.41 | 2019-2025 | |
| Amgen INC. | $234.07 | 2019-2025 | Evenity, Prolia, Prolia |
| Neurocrine Biosciences, INC. | $214.98 | 2022-2025 | Ingrezza |
| Dexcom, INC. | $203.34 | 2023-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $196.50 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $196.37 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $165.07 | 2020-2025 | Vraylar, Qulipta |
| Sanofi-Aventis U.S. LLC | $138.01 | 2019-2025 | |
| Glaxosmithkline, LLC. | $121.46 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Exact Sciences Corporation | $115.67 | 2023-2025 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $93.03 | 2022-2025 | Injectafer |
| Janssen Pharmaceuticals, INC | $84.93 | 2019-2023 | Spravato |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $80.20 | 2019-2023 | Trintellix |
| Astellas Pharma US INC | $76.63 | 2019-2024 | Veozah, Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $74.64 | 2024-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.87 | 2022-2025 | Jardiance |
| Abbott Laboratories | $68.88 | 2019-2024 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $65.24 | 2023-2025 | Nexletol |
| Sumitomo Pharma America, INC. | $64.92 | 2023-2025 | Gemtesa |
| Cequr Corporation | $55.56 | 2025 | Cequr Simplicity |
| Xeris Pharmaceuticals, INC. | $55.32 | 2023-2024 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $45.95 | 2024-2025 | Voquezna |
| Idorsia Pharmaceuticals US INC | $40.66 | 2022-2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $39.53 | 2022-2024 | Eliquis |
| Sunovion Pharmaceuticals INC. | $39.19 | 2019 | |
| Aimmune Therapeutics, INC. | $35.17 | 2025 | Zenpep |
| Lundbeck LLC | $27.64 | 2023 | Vyepti |
| Merck Sharp & Dohme LLC | $25.23 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Celgene Corporation | $20.41 | 2019 | |
| Stryker Corporation | $19.24 | 2025 | Clottriever Bold Catheter |
| Scilex Pharmaceuticals INC. | $17.30 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.09 | 2023 | |
| Mylan Specialty L.P. | $14.08 | 2019 | |
| Allergan, INC. | $14.01 | 2019 | |
| Acadia Pharmaceuticals INC | $11.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kirk Steptoe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.